Recently, Modena and vaccine giant MSD announced that the phase III clinical trial of the two companies to jointly develop the personalized mRNA cancer vaccine Intismeran Autogene combined with the PD-1 inhibitor pabolizumab to treat melanoma has achieved positive results. Both survival without recurrence and survival with no distant metastases have reached critical endpoints. As soon as the news came out, Modena's stock price soared 177% to $174.38 on the same day, a record high in many years. While sparking a frenzy in the capital market, the high price of the “cancer vaccine” is astonishing, and it is considered a game for the rich. According to China Newsweek quoting US investment bank William Blair's estimates, the wholesale procurement cost of this drug is about 475,000 US dollars, or about 3.18 million yuan. Zhan Qilin, chief physician of the Department of Hematology and Oncology at the Shanghai Public Health Clinical Center, also said in an interview with the media that currently, the drug is estimated to cost more than 100,000 US dollars per person, and it takes about 6 to 9 weeks from sampling to receiving the first dose.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.